Advertisement
Mayo Clinic Proceedings Home

SARS-CoV-2 Infections: An ACE in the Hole and Systems Biology Studies—a Research Agenda

      As of the time of this writing, severe acute respiratory syndrome (SARS) coronavirus (CoV) 2 has involved nearly every country, with almost 6 million identified cases. Of considerable interest has been the evolving information regarding the differential morbidity and mortality caused by this novel virus. Investigators from China have published data suggesting that the population-level case fatality rate in Wuhan was in the 2% to 4% range, whereas outside Wuhan but within China, it was in the 1% range. Even more interesting is that outside China, the case fatality rate has been generally lower—although markedly higher in Italy and among African Americans. Why these differences?
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cao Y.
        • Li L.
        • Feng Z.
        • et al.
        Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations.
        Cell Discov. 2020; 6: 11
        • Cai G.
        Tobacco-use disparity in gene expression of ACE2, the receptor of 2019-nCov.
        Preprints. 2020; : 2020020051
        • Hoffmann M.
        • Kleine-Weber H.
        • Schroeder S.
        • Krüger N.
        • Herrler T.
        • Erichsen S.
        • et al.
        SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.
        Cell. 2020; 181: 271-280.e8
        • Huang C.
        • Wang Y.
        • Li X.
        • et al.
        Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China (published correction appears in Lancet. 2020;395(10223):496).
        Lancet. 2020; 395: 497-506
        • Chen N.
        • Zhou M.
        • Dong X.
        • et al.
        Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
        Lancet. 2020; 395: 507-513
        • McMichael T.M.
        • Clark S.
        • Pogosjans S.
        • et al.
        • Public Health – Seattle & King County, EvergreenHealth, and CDC COVID-19 Investigation Team
        COVID-19 in a long-term care facility - King County, Washington, February 27-March 9, 2020.
        MMWR Morb Mortal Wkly Rep. 2020; 69: 339-342
        • Esler M.
        • Esler D.
        Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?.
        J Hypertens. 2020; 38: 781-782
        • Imai Y.
        • Kuba K.
        • Rao S.
        • et al.
        Angiotensin-converting enzyme 2 protects from severe acute lung failure.
        Nature. 2005; 436: 112-116
        • Vaduganathan M.
        • Vardeny O.
        • Michel T.
        • McMurray J.J.V.
        • Pfeffer M.A.
        • Solomon S.D.
        Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19.
        N Engl J Med. 2020; 382: 1653-1659
        • European Society of Cardiology
        Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. European Society of Cardiology website.
        (Published March 13, 2020. Accessed April 10, 2020)
        • American Heart Association
        HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. American Heart Association website.
        • Poland G.A.
        Tortoises, hares, and vaccines: a cautionary note for SARS-CoV-2 vaccine development [editorial].
        Vaccine. 2020; 38: 4219-4220